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Abstract
RNA-seq is a promising technology to re-sequence protein coding genes for the identification of single nucleotide variants
(SNV), while simultaneously obtaining information on structural variations and gene expression perturbations. We asked
whether RNA-seq is suitable for the detection of driver mutations in T-cell acute lymphoblastic leukemia (T-ALL). These
leukemias are caused by a combination of gene fusions, over-expression of transcription factors and cooperative point
mutations in oncogenes and tumor suppressor genes. We analyzed 31 T-ALL patient samples and 18 T-ALL cell lines by
high-coverage paired-end RNA-seq. First, we optimized the detection of SNVs in RNA-seq data by comparing the results
with exome re-sequencing data. We identified known driver genes with recurrent protein altering variations, as well as
several new candidates including H3F3A, PTK2B, and STAT5B. Next, we determined accurate gene expression levels from the
RNA-seq data through normalizations and batch effect removal, and used these to classify patients into T-ALL subtypes.
Finally, we detected gene fusions, of which several can explain the over-expression of key driver genes such as TLX1, PLAG1,
LMO1, or NKX2-1; and others result in novel fusion transcripts encoding activated kinases (SSBP2-FER and TPM3-JAK2) or
involving MLLT10. In conclusion, we present novel analysis pipelines for variant calling, variant filtering, and expression
normalization on RNA-seq data, and successfully applied these for the detection of translocations, point mutations, INDELs,
exon-skipping events, and expression perturbations in T-ALL.
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Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
malignancy that accounts for approximately 15% of pediatric and
25% of adult ALL cases. Despite improved outcome over the
years, about 25% of children and 50% of adults still fail to respond
to intensive chemotherapy protocols or relapse [1]. Improved
understanding of T-ALL biology through the identification and
characterization of oncogenic lesions is expected to lead to a better
prognostic classification and the development of new targeted
therapeutic strategies.
T-ALL is caused by the accumulation of multiple oncogenic
mutations that have been identified through characterization of
chromosomal aberrations and candidate gene sequencing [2].
Chromosomal translocations in T-ALL frequently involve the T-
cell receptor (TCR) loci, whereby TCR regulatory elements become
juxtaposed to genes that are normally not expressed in T-cells
[3,4]. In this way, a specific set of recurrently over-expressed
transcription factors (TFs) have been documented, including
TLX1, TLX3, TAL1, LMO1, HOXA, and NKX family members
[5]. T-ALL samples expressing each of these transcription factors
show a distinctive gene expression signature and as such these
transcription factors define distinct molecular subtypes in T-ALL
[6]. Chromosomal rearrangements can also lead to large
chromosomal deletions and amplifications; to focal gene deletions
or amplifications, such as CDKN2A deletion and MYB duplication
[7,8]; and to in-frame fusion genes encoding chimeric proteins
with oncogenic properties such as the constitutively active
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NUP214-ABL1 fusion kinase [9]. In addition, point mutations and
small insertions/deletions (INDELs) have also been described
leading to oncogenic events, such as mutations activating
NOTCH1 that occur in more than 60% of T-ALL cases [10], or
mutations in cytokine receptors and tyrosine kinases such as IL7R
and JAK3 [11–17]. The latter may lead to new opportunities for
molecularly tailored therapies with kinase inhibitors [12,16,18,19].
With the advent of next generation sequencing (NGS)
technologies, our sequencing capacity has significantly improved
in the past five years. It is now possible to apply targeted re-
sequencing, exome sequencing (Exome-seq), whole genome
sequencing (WGS), whole transcriptome sequencing (RNA-seq)
or a combination of these, to investigate individual genomes,
especially those related to disease [20]. Also for T-ALL, these NGS
approaches have recently proven their value in the discovery of
novel driver genes [13,14,17,21]. We previously identified a
spectrum of new oncogenic driver genes using Exome-seq on 67
T-ALLs, and described clear differences between pediatric and
adult patients [17]. In particular, we identified CNOT3 as a tumor
suppressor mutated in 8% of adult T-ALL cases and mutations
affecting the ribosomal proteins RPL5 and RPL10 in 10% of
pediatric T-ALLs [17]. Similarly, whole genome sequencing of
early T-cell precursor ALL cases led to the identification of
mutations in several new oncogenes and tumor suppressor genes
affecting cytokine signaling, T-cell development and histone-
modifying genes [2,13]. However, the potential of RNA-seq for
the discovery of driver genes in T-ALL remains unexplored.
In the present study, we applied paired-end RNA-seq on 49 T-
ALL samples (31 patients, 18 cell lines) to gain insights in the
transcriptome landscape of T-ALL. First, we show that identifi-
cation of somatic single nucleotide variants (SNV) and recurrently
mutated driver genes is feasible on RNA-seq data, even without
matched normal samples (e.g., germlines or remission DNA). We
identify STAT5B, H3F3A, and PTK2B as candidate cancer genes
in T-ALL. This becomes possible when (1) optimal read mapping
and SNV calling procedures are applied; and (2) functional
annotation, gene expression, or additional sequencing data from
other cohorts is used to prioritize the true driver genes. Next, we
optimized gene expression measurements using multiple normal-
ization strategies, and showed that classical gene expression studies
(e.g., clustering) are feasible on normalized RNA-seq data. We also
detected new fusion genes (SSBP2-FER and TPM3-JAK2) and used
gene expression data to determine the consequence of observed
chromosomal rearrangements on the over-expression of key driver
genes. Finally, we searched for significant alternative transcript
events (ATE) but besides one coherent exon-skipping event in
SUZ12, we found relatively few candidate ATEs in T-ALL. In
conclusion, through a combination of the analysis of gene
expression levels, fusion transcripts, SNVs, and INDELs, we could
identify known and new driver alterations in T-ALLs and novel
potential targets for therapy.
Results
Correct SNV and INDEL calling on RNA-seq data depends
on accurate read mapping
We performed paired-end RNA-seq on 31 T-ALL patients, 18
T-ALL cell lines, and 1 normal thymus sample. We obtained on
average ,110 million reads per sample, leading to an average
coverage of,886(Table S1.A). To assess the quality of detecting
SNVs from the RNA-seq data, we compared the RNA-seq to
Exome-seq data. For 16/18 of the cell lines and for 20/31 patient
samples we had exome data available (previously generated [17] or
obtained for this study, Table S2). For the exome data analysis,
we followed the pipeline of mapping, SNV and somatic mutation
detection that we validated previously [17] (using BWA, GATK,
SomaticSniper, and Variant Effect Predictor (VEP)) [22–25]. For
the RNA-seq data we used TopHat2 [26] for mapping, SAMTools
[27] for SNV detection, and VEP [25] for variant annotation
(Figure 1.A).
By comparing positions that had a coverage of at least 206 in
both RNA-seq and Exome-seq, combined with Sanger re-
sequencing of a subset of positions, we found that the accuracy
of SNV calling in RNA-seq strongly depends on the read
mapping, corroborating earlier observations [28,29] (Figure
S1). We found that mapping RNA-seq reads to the genome (as
used by TopHat version 1.3.3) is prone to errors when dealing
with paralogous genes, as observed by the prediction of false
positive SNVs in KIF4A and GLUD1 due to erroneous mapping to
KIF4B and GLUD2 (both pseudogenes with no introns) (Figure
S1). However, these errors were resolved by mapping to the
transcriptome. In the case of the RPMI8402 cell line, 877 SNVs
were found by mapping to the genome, while this number was
reduced to 283 SNVs when mapping to the transcriptome.
Mapping to the transcriptome did not only reduce the number of
RNA-seq exclusive calls but also increased the overlap with the
Exome-seq calls (Figure 2, Figure S2).
However, transcriptome mapping also has limitations as it relies
on current gene and isoform annotation. We observed that a
combination of transcriptome and genome mapping provides the
best solution. It is important that all reads are mapped twice to the
genome, independently of each other; once as entire read and
once as split read. This has become possible in TopHat2 by setting
the option ‘‘read-realign-edit-dist’’ to zero. Our analysis reveals that
this mapping approach results in the best overlap of SNVs
compared to exomes (Figure 2, Figure S3). This mapping
strategy not only improves the alignment accuracy by preventing
misalignment to pseudogenes, but also leads to identification of the
most likely isoform structure of a gene by mapping the reads
Author Summary
The quest for somatic mutations underlying oncogenic
processes is a central theme in today’s cancer research.
High-throughput genomics approaches including ampli-
con re-sequencing, exome re-sequencing, full genome re-
sequencing, and SNP arrays have contributed to catalogu-
ing driver genes across cancer types. Thus far transcrip-
tome sequencing by RNA-seq has been mainly used for
the detection of fusion genes, while few studies have
assessed its value for the combined detection of SNPs,
INDELs, fusions, gene expression changes, and alternative
transcript events. Here we apply RNA-seq to 49 T-ALL
samples and perform a critical assessment of the bioinfor-
matics pipelines and filters to identify each type of
aberration. By comparing to exome re-sequencing, and
by exploiting the catalogues of known cancer drivers, we
identified many known and several novel driver genes in T-
ALL. We also determined an optimal normalization
strategy to obtain accurate gene expression levels and
used these to identify over-expressed transcription factors
that characterize different T-ALL subtypes. Finally, by PCR,
cloning, and in vitro cellular assays we uncover new fusion
genes that have consequences at the level of gene
expression, oncogenic chimaeras, and tumor suppressor
inactivation. In conclusion, we present the first RNA-seq
data set across T-ALL patients and identify new driver
events.
T-ALL Transcriptome Variation
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independently both to the transcriptome and to the genome and
then selecting the best possible alignment.
Using the optimized mapping and filtering strategy we identified
436,974 SNVs across 49 samples. By using samples for which both
the exome and the transcriptome were sequenced several aspects
of SNV detection in RNA-seq data can be evaluated, such as
sensitivity, specificity, and allelic imbalance. Regarding sensitivity,
we found that on average, 32% of the SNVs that are called in
Exome-seq were also called by the RNA-seq (Table S3). Similar
ratios were observed when comparing validated somatic SNVs
from Exome-seq/WGS to RNA-seq SNVs: 36% in a triple
negative breast cancer study [30], and 41% in a lymphoma study
[31]. We observed that the sensitivity varies considerably between
samples, and strongly correlates with the average depth of
coverage of the sample (Figure S4). Regarding specificity, we
found that the remaining RNA-seq-only and Exome-seq-only
SNVs (for positions where both have at least 206 coverage) are
found mainly with a low variant allele frequency (VAF) and are
therefore likely due to arbitrary VAF and coverage thresholds. For
example, on the RPMI8402 and TLE79 samples, many RNA-seq-
only SNVs (9/18 and 61/88 respectively) have a VAF below 40%.
Regarding allelic imbalance, we found that of all heterozygous
Exome SNVs with more than 206coverage, the majority (2,914/
4,043 or 72%) were also heterozygous SNVs in RNA-seq. Of the
remaining SNVs, many (988/4,043) are homozygous reference in
the RNA-seq (i.e., not detected). A small fraction we can almost
certainly attribute to allelic imbalance, namely the 141/4,043
SNVs (3.5%) that are homozygous variant in the RNA-seq,
indicating that for those only the variant allele is expressed (or the
gene is only expressed in cancer cells that harbor the variant).
Next we asked whether small insertions and deletions (INDELs)
can be detected from RNA-seq data. As with the SNVs, we used
the Exome-seq data for assessing the quality of our INDEL
detection strategy. On average, 47.5% of the INDELs that were
detected by RNA-seq were also found in the Exome-seq
(unfiltered) INDEL calls. However, only 4% of the Exome-seq
INDELs (for which the region containing INDEL is covered by at
least 3 reads in RNAseq data) were found back in the RNA-seq
calls (Table S3). To investigate this sensitivity issue, we evaluated
ten validated INDELs that we previously identified with Exome-
Seq [17](Table S4). Three of the ten INDELs were also identified
in the RNA-seq data using the default SAMTools parameters (see
Materials and Methods). Of the seven missed INDELS, two are
found in a gene that is not expressed; another two are clearly
present in the RNA-seq data when inspected manually with IGV,
but did not reach the default threshold (see Materials and
Methods); and the last three are effectively discordant between
RNA-seq and Exome-seq, as they show only reads with reference
sequence (Figure S5). Re-mapping of the reads with BWA [22]
on the transcriptome followed by BLAT [32] on the genome
improved the INDEL identification, now revealing the KDM6A
INDEL in TLE87 and PTEN INDEL in TLE92, which were
previously missed (Figure S6.A–B). It is notable that the
combination of TopHat2 (to transcriptome only) and BLAT does
not correctly detect these two INDELS (Figure S6.C–D). We
conclude that INDEL detection on RNA-seq data is feasible, yet
technically challenging and that the fraction of INDELs compared
to SNVs is moderate (see also the next Section and Figure 3).
Leveraging diagnosis-only RNA-seq data with the T-ALL
body of knowledge to identify mutated cancer genes
Our next aim was to select candidate driver genes using the
collected SNVs and INDELS. To remove germline variants we
initially removed all SNPs present in dbSNP [33], 1000genomes
[34], the Complete Genomics genomes [35], and those detected in
our own exome data from normal samples (39 from our earlier
work [17] and 6 from this study). We, however, retained those
Figure 1. RNA-seq data analysis pipelines for (A) variant calling and filtering to detect point mutations, (B) fusion detection and
annotation, (C) gene expression analysis.
doi:10.1371/journal.pgen.1003997.g001
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variants also present in the COSMIC [36] database, since SNP
databases are known to contain also some disease-specific SNVs.
Some examples of SNVs that are likely driver mutations, but that
are also present in polymorphism databases are: JAK3 A572V in
R7, and FBXW7 R425C in TUG1. With this filtering, we
obtained a final list of 10,403 protein-altering SNVs and 430
protein-altering INDELs, with a median of 63 SNVs and 4
INDELS per sample (Table S1.B). Cell lines harbored signifi-
cantly more mutations than patient samples (Mann-Whitney test
p-value = 1.095E-05), as previously also observed by Exome-seq
[17].
As a first approach to identify candidate T-ALL driver genes,
we selected all genes that contained a protein-altering mutation in
at least two of the 31 patient samples (for recurrence we did not
take cell lines into account). This process resulted in the selection
of 213 genes (Table S5). We found that this list is strongly
enriched for genes related to T-ALL and to cancer in general, with
‘‘precursor T-cell lymphoblastic leukemia-lymphoma’’ as the most
Figure 2. Comparison between RNA-seq and exome-seq. Variant Allele Frequency plots for evaluating two RNA-seq mapping strategies for
two example samples, namely the RPMI8402 cell line (A, B) and the TLE79 patient sample (C, D). On the left are the results of mapping with TopHat
1.3.3. (A,C), while on the right are the results of mapping with TopHat 2.0.5 with forced re-mapping of all reads to the genome. The SNVs that have at
least 20 reads in exome-seq and RNA-seq are plotted. Red and green dots represent the SNVs that are detected only in RNA-seq and only in exome-
seq, respectively, while black dots represent the SNVs that are called in both. Venn diagrams are produced from the points represented in the graphs.
doi:10.1371/journal.pgen.1003997.g002
T-ALL Transcriptome Variation
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Figure 3. Point mutations and gene fusions organized into functional categories. Protein altering mutations and INDELs, alternative
splicing events and validated fusions are shown. Red boxes indicate protein-altering mutations (i.e. nonsense, missense and splice site mutations);
purple boxes indicate frame-shift INDELs whereas blue, green and orange boxes represent fusion events resulting in over-expression of the partner
gene, inactivation of the partner gene or generation of a chimeric protein, respectively, and finally black boxes indicating alternative splicing events.
doi:10.1371/journal.pgen.1003997.g003
T-ALL Transcriptome Variation
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highly enriched function (p-value = 1.35E-11 by Ingenuity Path-
way Analysis) (Table S6). The list of 213 candidates contained
many known T-ALL driver genes (Figure 3), such as NOTCH1,
BCL11B, FBXW7, IL7R, JAK1 and JAK3; and it also contained the
drivers CNOT3 and RPL10, recently identified in our exome re-
sequencing study [17]; and CTCF, which was recently reported to
be recurrently mutated in ETP-ALL [13]. In addition, the
candidate list contained two established cancer driver genes
involved in other cancer types, but not yet reported to be mutated
in T-ALL, namely H3F3A and CIC. These genes were reported
recently by Vogelstein [37] to be true cancer drivers. We identified
two patient samples (TLE76 and TUG6) with H3F3A mutations
both on the K28 residue that is a mutational hotspot in
glioblastoma [38]. This mutation was confirmed somatic in the
TUG6 sample. Sequencing of this hotspot in additional T-ALL
samples indicated a low frequency of H3F3A K28 mutation in T-
ALL (detected in 3 of 102 cases).
Next we asked if we could identify additional genes in the
candidate list that could be linked to T-ALL. We wanted to utilize
the genes that are known to be involved in T-ALL as a guide for
identifying additional candidates. To this end we used our gene
prioritization approach ENDEAVOUR [39], which scores candi-
date genes based on a set of training genes. It builds a profile based
on the training genes (integrating information on protein-protein
interactions, genetic interactions, gene expression, text-mining,
sequence homology, Gene Ontology, and protein domains) and
then prioritizes the candidate genes for their similarity to the
derived profile. As training set we used all known drivers, and as
test set we used all the 213 candidates with at least two patient
mutations (excluding the genes that are in the training set). We
reasoned that this would reveal the genes with strong similarity to
the known drivers and such genes would be good candidate
drivers. We found 45 significantly ranked genes with two
interesting genes at the top of the ranking, namely PTK2B and
STAT5B that are involved in JAK/STAT signaling (Table S7).
Furthermore, the list contained genes for which we had identified
single T-ALL cases with a somatic mutation in our previous exome
study: ANKRD11, CTCF, DOCK2, H3F3A, and HADHA. We did
not select these genes before in our Exome-seq cohort [17] because
they were only mutated in one of the 39 samples we analyzed.
Now, with the RNA-seq cohort, we thus found additional samples
with mutations in these genes.
Optimized gene expression measurements and batch
effect removal from RNA-seq data identify co-expression
modules and T-ALL subtypes
T-ALL is characterized by the overexpression of transcription
factors (TFs), such as TLX1, TLX3, TAL1, and the HOXA family
members [6]. Therefore, identifying and analyzing expression
perturbations in a T-ALL cohort is highly relevant. To obtain
accurate gene expression levels from the mapped RNA-seq reads,
we followed the procedure outlined in Figure 1.B, including read
aggregation, GC-normalization, length normalization, and be-
tween-sample normalization (see Materials and Methods). In
addition, we removed a batch effect that was clearly present in the
data set using a Generalized Linear Model (GLM, see Materials
and Methods) (Figure S7). It is notable that transcript-based
expression analysis conducted with cufflinks revealed the same
batch effect linked to the origin of the sample, thereby confirming
a technical bias in the data set (Figure S7.B, see Materials and
Methods).
We next looked at the expression values of TLX1, TLX3, TAL1,
and other important TFs in T-ALL. Clustering of TLX1, TLX3,
and TAL1 expressing samples confirmed that the correct samples
(based on karyotyping and molecular analysis) showed over-
expression of the respective TF (Figure 4.A). Indeed, 8 samples
that harbored a STIL-TAL1 rearrangement showed high TAL1
expression (Figure 4.D). Note that also other samples with high
TAL1 expression were detected. This fits with a previously
reported observation of TAL1 over-expression in the absence of
a translocation in T-ALL [6,40].
To assess the accuracy of our expression values obtained after
normalization, batch effect removal and clustering, we tested
whether previously published gene signatures associated with
TAL1, TLX (TLX1 and TLX3) and LYL1 can be detected also in
our data set [41]. We used 13 gene signatures obtained by Soulier
et al using a microarray study on 92 primary T-ALL samples [41].
Gene set enrichment analysis shows that our TAL1 expressing
cases are significantly associated with TAL1 signatures, whereas
our TLX over-expressing cases are associated with the TLX
signature [7,8] and the LYL1 cases with the LYL1 signature
[10,11]. This analysis confirms that the obtained expression data
represent meaningful values and sample clustering produces gene
lists that are biologically meaningful (Figure 4.B).
We next used the gene expression information as a guide to
assist in the detection of relevant mutations. We found that the
expression profile of PTK2B, a candidate driver identified above
by ENDEAVOUR, significantly correlated with the JAK3
expression profile (PTM, with p-value threshold at 1E-05, see
Materials and Methods) (Figure 4.C). Indeed, PTK2B was
previously implicated in IL-2 mediated signaling and JAK/STAT
signaling, and was shown to physically interact with JAK3 [42].
These data warrant further investigation of PTK2B as an
important tyrosine kinase in T-ALL case with activated JAK/
STAT signaling.
T-ALL presents robust transcript isoform usage
To our knowledge, only very few cancer specific alternative
transcript events (ATE) have been described for any cancer type
[43–45], and no ATE is reported for T-ALL. In contrast to SNVs,
INDELS, copy number variations, and fusions, which are all
curated and present in large numbers in public cancer mutation
databases (e.g., COSMIC [36], CENSUS [46]), we could not find
driver ATEs in those databases (although splice sites represent an
important class of cancer mutations). If ATEs represent an
important, yet underestimated, type of somatic variation in cancer,
we would expect at least some of the known cancer driver genes to
present a significant ATE. We thus asked whether novel variations
could be found in these genes in the form of ATEs. To this end, we
applied cufflinks and cuffdiff (see Materials and Methods) and found
significant ATEs in 12 of the 47 known driver genes (BCL11B,
FLT3, IL7R, LCK, MYB, NKX2-1, SFTA3, RPL10, RUNX1,
SETD2, SUZ12, and TAL1) (Table S8). However, when we
manually inspected these events in IGV, we found only two
interesting cases. One case represents an unambiguous skipping of
exon 7 in SUZ12, occurring in several patient samples, but most
significant (cuffdiff p-value = 5.10E-05) in the R5 patient sample,
and absent in the Thymus (Figure 4.E), and a potential, but less
clear, skipping of exon 8 in LCK in three samples (Figure S8).
Exon 7 of SUZ12 is a canonical exon (present in all known
isoforms) according to RefSeq, Ensembl, and UCSC annotation.
The ATE we observe is a heterozygous event with the wild-type
junction supported by 90 reads and the novel junction supported
by 71 reads. RT-PCR clearly confirmed the exon-skipping event
in R5 and to a minor extent in other samples, while being absent
in the thymus (Figure 4.F). The functional consequences of these
splice variants remain to be determined, but the fact that these
variants are both in-frame suggests that these proteins could be
T-ALL Transcriptome Variation
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functional protein isoforms (Figure S8 and S9). Overall,
relatively few significant ATEs are detected, and no obvious
ATEs are found with consequences on the protein structure,
therefore T-ALL presents robust isoform usage at the current
resolution of sequencing and analysis.
Detection and validation of known and novel fusion
transcripts
Most of the T-ALL cases harbor chromosomal rearrangements
that lead to the generation of fusion genes or ectopic expression of
genes due to juxtaposition to strong promoters or regulatory
sequences. Chromosomal translocations involving the TCR genes
are largely underestimated by karyotyping and the TCR partner
genes remained unidentified in several cases [4,47]. On the other
hand, a multitude of mechanisms other than translocations could
cause ectopic expression of oncogenes [48]. To detect fusion
transcripts, we used the defuse algorithm on our entire dataset
[49]. Briefly, this method identifies candidate gene fusions by
discordant alignments produced by spanning reads (each read in
the read pair aligns to a different gene) and by split reads (reads
that harbor a fusion boundary). The total number of predicted
fusions initially was 1,160 and 1,265 in patient and cell line
samples, respectively. Also in normal thymus RNA, 60 fusion
transcripts were detected. Next, we implemented additional filters,
considering only predictions supported by 8 or more spanning
reads and 5 or more split reads. Furthermore, we removed fusions
involving ribosomal genes, mitochondrial genes and fusions
between adjacent genes, as these could be caused by read-through
or trans-splicing [50,51] (Figure 1.C).
After applying these filters, we obtained an average of 5.5 fusion
events per patient sample and 11.1 per cell line (Table S1.C). In
total, 397 candidate genes are involved as potential partner in a
gene fusion (Table S9). Details on the fusion breakpoints and
validation of the novel candidate fusion transcripts are reported in
Tables S9 and S12 (see also Materials and Methods: RT-PCR and
Sanger Sequencing).
First, to determine the relevance of these predicted fusion
transcripts we looked at functional enrichment of these genes. 278
of 397 genes correspond to functionally annotated protein-coding
genes according to DAVID functional enrichment [52,53].
Furthermore, this set is strongly enriched for cancer-related genes,
and more specifically for genes involved in Acute Myeloid
Leukemia (p-value = 4.48E-10) and T-ALL (p-value = 4.47E-05),
including TP53, STAT5B, NOTCH1, IL7R, IKZF1, CDKN2A,
MLLT10, ETV6, and ABL1.
Second, we specifically analyzed the 27 in-frame fusions,
predicted to encode chimeric proteins (Table S10). This list
contained known oncogenic fusion genes, including NUP214-ABL1
(n = 2), MLL-FOXO4 (n = 1), PICALM-MLLT10 (n = 1), ETV6-
NCOA2 (n = 1) and SET-NUP214 (n = 1). In addition, we identified
3 novel chimeric transcripts in T-ALL, namely NUP98-PSIP1
(n = 1), TPM3-JAK2 (n = 1) and SSBP2-FER (n = 1) and a novel
DDX3X-MLLT10 fusion transcript (n = 1) recently described in a
pediatric T-ALL patient [54]. Conventional cytogenetic analysis
confirmed the presence of a t(X;10) in the case with the DDX3X-
MLLT10 fusion, whereas it failed to detect the chromosomal
rearrangements for the TPM3-JAK2, NUP98-PSIP1 and SSBP2-
FER fusions, demonstrating the power of RNA-seq to identify
cryptic fusion genes and to provide genetic information even in
patients with uninformative cytogenetics. Reassuringly, RT-PCR
and Sanger sequencing confirmed the presence of these fusion
transcripts (Table S12).
The TPM3-JAK2 and SSBP2-FER fusions encode typical
tyrosine-kinase fusions that join the tyrosine-kinase domain of
JAK2 or FER to the dimerization units of TPM3 or SSBP2,
respectively (Figure 5.A). To assess whether the TPM3-JAK2 and
SSBP2-FER fusions encode oncogenic proteins, we tested their
transforming properties in the IL-3–dependent Ba/F3 cell line
[55]. Both TPM3-JAK2 and SSBP2-FER transformed Ba/F3 cells
to IL-3–independent growth, with even faster kinetics than the
JAK1 A634D mutant, which is a known transforming kinase [18]
(Figure 5.B). Western blot analysis confirmed the constitutive
auto-phosphorylation of the JAK2 and FER fusion proteins, as well
as the downstream STAT proteins (Figure 5.C). Ba/F3 cells
transformed by the TPM3-JAK2 fusion were sensitive to a JAK
kinase inhibitor, documenting the potential application of JAK2
kinase inhibitors for the treatment of T-ALL cases with JAK2
fusion genes. No specific FER inhibitors were available to test their
activity. Both TPM3-JAK2 and SSBP2-FER fusion were screened
in 50 additional T-ALL samples, but no additional case with these
fusions was found.
Third, we also analyzed the identified fusions that did not seem
to encode chimeric proteins (out-of-frame fusions), and which were
the majority of fusions detected in T-ALL. These fusion events can
be used as surrogate markers for the identification of chromosomal
rearrangements, providing accurate information on the precise
chromosomal breakpoints. In combination with the gene expres-
sion data obtained by RNA-seq, these data can identify genes that
are located close to such potential breakpoints and for which the
expression is significantly up- or down-regulated. As expected, we
identified the STIL-TAL1 fusion in several T-ALL cases (n = 8).
We also identified and validated 6 fusion events involving TCR
genes. In 4 of these cases, the TCR gene was found to be fused to
the potential oncogene (NOTCH1, IL7R, PLAG1, and TLX1). In
the two other cases (R4, TLE90), the TCR gene was fused to RIC3
or SFTA3, resulting in the ectopic expression of LMO1 and NKX2-
1, respectively, as indicated by RNA-seq gene expression data
(Figure 5.D and E). Similarly, we could better characterize the
t(10;14) in ALL-SIL cell line that expresses TLX1 at high level.
In addition to the TCR gene rearrangements, also other fusions
were associated with overexpression. We detected out-of-frame
fusion transcripts that joined exon 4 of CDK6 to exon 2 of
Figure 4. Validation and discovery using gene expression data, and SUZ12 ATE. (A) Classification of the samples using the TFs that are
known to be overexpressed in T-ALL. Using the expression patterns of TAL1, TLX1, TLX3, NKX2-5, LYL1 and LMO2 we could discriminate the samples in
to six distinct clusters. The heatmap is plotted with the normalized log2(count) values. Gene set enrichment analysis curves are displayed for (B)
enrichment of TAL1 associated clusters 2, 6 and 3 in TAL1 based ranking, (C) enrichment of TLX associated clusters 7 and 8 in TLX based ranking, and
(D) enrichment of LYL1 associated clusters 10 and 11 in LYL1 based ranking of the genes. (E) Expression of JAK3 and PTK2B across samples is
significantly correlated (with PTM p-value= 1E-05). (F) Normalized expression values of TAL1 and TLX1 with translocations affecting these genes
indicated. The samples with a translocation have elevated expression of the affected gene, showing the driver potential of the fusion event. There are
additional samples with high expression of TLX1 and TAL1 without the indicated fusions, pointing to other mechanisms of activating these genes. (G)
Predicted SUZ12 transcript aligned with the known SUZ12 isoforms. Dotted red box indicates the location of the exon-skipping event. (H) The sashimi
plot shows the junction (in black) supporting the exon-skipping event in patient sample R5 with respect to Thymus. (I) Agarose gel electrophoresis of
the RT-PCR products for validation of SUZ12 exon skipping event. The two isoforms are clearly detected in R5 and to a minor extent in the other T-ALL
samples while Thymus shows only the canonical transcript.
doi:10.1371/journal.pgen.1003997.g004
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Figure 5. SSBP2-FER and TPM3-JAK2 fusions transform lymphoid cells and show constitutive activity. (A) Schematic representations of
the predicted SSBP2-FER and TPM3-JAK2 fusion joining the dimerization units of SSBP2 (LisH domain) or TPM3 (coiled-coil domains) to the TK domain
of FER or JAK2, respectively. (B) Proliferation curve of mouse Ba/F3 cells in the absence of the cytokine interleukin 3 (IL3) (upper graph) and in the
presence of ruxolitinib (lower graph). In the absence of IL3, cells expressing empty vector died whereas cells expressing the SSBP2-FER or TPM3-JAK2
fusion protein were transformed and could proliferate. Ba/F3 cells expressing the oncogenic JAK1 A634D mutant were used as positive control for
transformation [18]. The graph shows mean +/2 st. dev. The lower graph illustrates the effects of the JAK kinase inhibitor ruxolitinib on Ba/F3 cell
T-ALL Transcriptome Variation
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HOXA11-AS and exon 5 of CDK6 to sequences downstream of
EVX1. In the same patient we also detected a fusion joining
DPY19L1 on chromosome 7p14 to HOXA11 on chromosome
7p15. The gene expression analysis documented high expression
of genes of the HOXA cluster (i.e. HOXA9, -A5, -A13, -A10, -A11).
Moreover, other fusions identified in this study, such as CLINT1-
MEF2C, HNRP-ZNF219 (n = 2), ZEB1-BMI1 and AHI1-MYB
(n = 2) were also associated with transcriptional activation of
MEF2C, ZNF219, BMI1 and MYB as confirmed by the expression
data (Table S9 and S12, and Figure S10). Increased MYB
expression in T-ALL was previously observed as a consequence of
MYB duplication (including in the BE-13 cell line), which may also
explain the detected AHI1-MYB fusion [8,56].
Finally, we also found out-of-frame fusion transcripts leading to
the potential inactivation of tumor suppressor genes, such as
TP53-TBC1D3F (ALLSIL cell line), PTEN-RNLS (LOUCY cell
line), IKZF1-ABCA13 and CDKN2A-miR31HG (R6 case), indicating
a third class of fusion events (Figure S10). FISH analysis
performed in the R6 case confirmed the p15/p16 deletion. As
the genes are in close proximity, the IKZF1-ABCA13 was
presumably generated by deletion although no material was
available to confirm this hypothesis.
Discussion
The landscape of genomic variation underlying T-ALL has
recently been investigated by sequencing candidate genes [14,21],
whole exomes [17] and whole genomes [13]. The results of these
studies, combined with a large body of gene-by-gene evidence
collected over the last decade, provide a growing comprehension
of the T-ALL genome. The T-ALL genome is mainly character-
ized by the over-expression of TF, such as TLX1/3 and TAL1, in
combination with gain-of-function NOTCH1 mutations, and with
additional mutations in chromatin modifiers, cellular signaling
factors such as those involved in the JAK-STAT signaling pathway
[57], tumor suppressor genes (TP53, PTEN, WT1), or in other
genes such as ribosomal genes [17]. Since the majority of observed
mutations are point mutations and gene fusions (much more than
copy number variations [13]) we reasoned that RNA-seq would be
effective to identify many of these mutations, certainly those
associated with (over-)expressed oncogenes. Indeed, exome
sequencing allows identifying point mutations but not gene
fusions; and low coverage whole-genome sequencing allows
identifying structural variation (gene fusions) but not point
mutations. In this study we present RNA-seq analyses on a
heterogeneous group of 31 T-ALL samples and 18 T-ALL cell-
lines and demonstrate that RNA-Seq is indeed a very powerful
approach to detect gene mutations and fusions as well as
expression perturbations.
Our first challenge with regards to the accurate identification of
point mutations was finding the optimal analysis pipeline – from
read mapping to SNV calling and filtering – to avoid too many
false positive SNVs. By exploiting whole-exome sequencing data
for a subset of our samples we obtained a recovery ratio of 32%
when compared to the exome derived SNVs; a ratio that is
comparable with previous RNA-seq studies [30,31]. However, this
concordance could only be achieved by using the optimal read
mapping methods and parameters: (1) use of a recent version of
TopHat2 (v. 2.0.5. or higher) and (2) forcing this aligner to map all
reads twice to the genome (once directly and once using split reads)
and once to the transcriptome. Indeed, the computational task of
sequence read mapping is more challenging for RNA-seq data
because a large fraction of the obtained reads need to be split to
allow reads that overlap exon-exon boundaries in the cDNA to be
mapped to the genome. In this way, RNA-seq is more prone to the
identification of false SNVs due to the erroneous mapping of
reads, for example to highly similar non-spliced pseudogenes. For
example, in the RPMI8402 cell line, 603 RNA-seq exclusive SNVs
were found with the genome mapping strategy, while only 35
when using combined mapping strategy.
Among the previously published large scale RNA-seq cancer
studies, only a handful performed variant calling on the RNA-seq
data [30,31,58,59]. A combined mapping strategy was followed in
all cases either by mapping the reads to a customized genome
reference file (by the addition of exon junction segments) or
mapping the reads twice (once to the genome and once to the
transcriptome). Variant calling pipelines also showed diversity:
Morin et al and Shah et al used SNVMix [60] for variant calling,
while Seo et al and Berger et al implemented filters based on
alignment on the non-reference bases. To our knowledge there is
no extensive benchmarking study evaluating aligners and variant
callers for RNA-seq data, but a review paper by Quinn et al
compared the performance of two variant callers (GATK [23] and
SAMTools [27]) with the optional duplicate removal step (pre and
post alignment), and concluded that post-alignment duplicate
removal and variant calling with SAMTools achieved the best
performance in terms of sensitivity and specificity [61]. We have
also followed the same strategy in our study and we could achieve
a comparable recovery ratio of 32% when compared to Exome-
seq calls.
A second challenge in identifying point mutations was the
prioritization of candidate driver mutations versus passenger
mutations. Due to the lack of matched germline RNA for each
patient as control, we used a large cohort of local normal exome
datasets, in combination with the commonly used variants from
dbSNP and 1000genomes, to distinguish SNPs from candidate
somatic mutations. This strategy has been successfully used before
on transcriptome sequencing studies [62]. Identifying candidate
cancer genes by gene mutation frequency is a frequently used
approach [13,30,58]. Remarkably, by simply selecting all genes
having a candidate somatic mutation in at least two samples (213
genes in total), we already achieved a highly significant enrichment
for T-ALL related genes, such as NOTCH1, BCL11B, FBXW7,
DNM2, JAK3, JAK1, and IL7R. Among the remaining candidates
we searched for additional evidence and we propose seven
additional candidate drivers because they are either ‘‘functionally
similar’’ to the previously known drivers, or because they were
mutated somatically at least once in another T-ALL cohort [17],
or both. Six of these genes, namely CIC, H3F3A, PTK2B, STAT5B,
ANKRD1 and HADHA have already been implicated in other
cancers [63–70] while DOCK2 has no association with cancer yet.
proliferation after 24 hours of treatment. The graph represents mean +/2 st. dev. of triplicate measurements. (C) Western blot analysis of Ba/F3 cells
transformed by the indicated kinases. The 2 upper panels show phosphorylation of the JAK and FER kinases, the panels below illustrate
phosphorylation of downstream targets STAT5, STAT3, SRC and ERK1/2. (D) TCR gene fusions result in overexpression of a flanking gene in RIC3-TRBC2
and SFTA3-TRDC fusions. The barplot is drawn for relative (to Thymus) expression values for the upstream and downstream flanking genes around
RIC3 and SFTA3 for R4 and TLE90 samples, respectively. In both cases, the nearest downstream neighbor shows increased expression. (E) The
heatmap illustrates the expression patterns of RIC3 and SFTA3, together with their immediately upstream and downstream flanking genes in the
genome, showing strong over-expression (red) of LMO1 near the RIC3 fusion, and of NKX2-1 near the SFTA3 fusion.
doi:10.1371/journal.pgen.1003997.g005
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We found a remarkable clustering of molecular functions
among the identified T-ALL driver genes, with enrichment for
functions related to the regulation of gene expression. TFs and
their co-factors play a central role in transcriptional regulation and
these proteins are often mutated in T-ALL. Also, many of these
play important roles in the normal T-cell developmental gene
regulatory network [71], such as NOTCH1, TLX1, TLX3, TAL1,
BCL11B, CTCF, FOXO4, MYB, and others. Upstream of these
activated TFs, multiple kinases and other signaling factors control
their activity, and these regulators are also often mutated in T-
ALL (for example, JAK1, JAK3, and IL7R). Finally, chromatin
modifiers and methylation factors are recurrently mutated and
these can have both generally pervasive but also specific effects on
the expression of oncogenes, such as MYC [72]. When multiple
driver mutations are serially acquired, their combined effect will
result in oncogenic expression profiles, whereby genes supporting a
growth advantage increase and genes negatively affecting growth
advantage (e.g., apoptosis, senescence) decrease in expression. It
will be an interesting future challenge to draw the connections
between the observed DNA mutations, the oncogenic program,
and the final gene expression changes that we and others observe
in T-ALL samples. Finally, it is likely that non-coding mutations,
such as those in promoters, enhancers, microRNAs, and lncRNAs,
add to the cancer-related gene regulatory network changes
underlying leukemogenesis.
As mentioned above, only mutations in genes that are actively
transcribed are detected, and this likely adds to the specificity of
driver gene detection. On the other hand, this could also present a
limitation of RNA-seq, because loss-of-function mutations in
tumor suppressor genes may lead to nonsense-mediated decay,
and as consequence low sequence coverage to call mutations.
Based on our data however, this is not the case because we could
detect PHF6 mutations in up to 4/31 patient cases (13%), where
exome sequencing identified PHF6 mutations in 9/67 cases (13%)
[17] and Zhang et al identified PHF6 mutations in 24/106 cases by
means of whole genome sequencing and capillary sequencing [13].
Interestingly, the gene expression information used above (i.e.,
read coverage to identify point mutations) can be further exploited
at the quantitative level, similar to gene expression studies
performed with microarray technology over the last 15 years. As
many leukemia driver genes are characterized by changes in gene
expression, this level of information is invaluable, both in research
and diagnostic settings. We investigated how accurate gene
expression levels can be achieved and we found that multiple
normalization steps are required, both within-sample (gene length
and gene GC content) and across samples (library size), and that
batch effects can be effectively removed using a previously
published Generalized Linear Model (GLM) [73]. The gene
expression levels of the known drivers (e.g., TLX1/3, TAL1,
NOTCH1) are highly representative as driving events and as
subtype identifiers. However, to discover driver genes de novo, using
only gene expression values, is to our opinion not feasible (data not
shown). Alternatively, we attempted to select candidate drivers
based on the expression similarity (i.e., co-expression across the
cohort) with known drivers. This led to the identification of
PTK2B, whose expression strongly correlated with JAK3 and
which is known to be implicated in JAK-STAT signaling. The
next level of gene expression analysis would preferably be a
network-level analysis [74], but this requires a larger sample
cohort.
Another kind of information that can be extracted from RNA-
seq data, besides point mutations and gene expression changes, are
alternative transcript events (ATE) and gene fusions [75]. We
found only few significant ATEs but could confirm two exon-
skipping events in the known T-ALL oncogenes SUZ12 and LCK.
More importantly, we identified (i) known and novel in-frame
fusions encoding chimeric proteins, (ii) TCR gene arrangements
resulting in over-expression of oncogenes, and (iii) fusions not
involving TCR genes but also resulting in over-expression of
oncogenic transcription factors. The most recurrent fusion event,
observed in 8/31 samples, was the STIL-TAL1 fusion resulting in
the ectopic over-expression of the TAL1 gene. We also identified
novel gene fusions, including two in-frame fusions, TPM3-JAK2
and SSBP2-FER, producing chimeric oncoproteins; and other
fusions resulting in the ectopic expression of transcription factors
such as PLAG1, MEF2C, ZNF219, and BMI1. The ectopic
expression of these genes is associated with a fusion event and
with changed expression, which can both be detected by RNA-
seq, making this technology extremely powerful to accurately
detect such oncogenic events. Each of these novel events appears
to be rare in T-ALL, as we identified at most 2 cases of each
fusion. However the evidence of transcriptional activation of the
partner genes suggests that further studies are required to establish
the recurrence of these lesions and their functional meaning. It is
notable that the normal thymus sample also shows four fusion
events. However, as these genes are located in close proximity to
each other, they may represent unannotated isoforms in the
human transcriptome. Despite RNA-seq has offered a deeper
insight into the complexity of the transcriptome, several studies
have highlighted that the catalogue of all expressed transcripts is
still far from complete and it is increasing the number of novel
splice junctions connecting novel exon, non-exon regions, or
linking independent transcripts [76].
Today, high-quality catalogues of driver genes across cancer
types are available, and this influences how and why cancer
genomes need to be sequenced. For T-ALL, and for many
common cancer types, the objectives of sequencing are shifting
from the discovery of cancer genes, to a diagnostic setting in which
a list of driver events are a priori known. Targeted re-sequencing
provides an interesting route, although this poses technical
challenges of amplification or capturing, and perhaps more
importantly, is focused on a limited number of genes and on
one particular mutation type, namely point mutations and small
insertions/deletions. We have shown in this study that, with a list
of interesting cancer drivers at hand, and with other datasets being
available (e.g., rare variants from local exome studies, 1000
genomes, TCGA data, etc), RNA-sequencing of only the cancer
sample provides a technically straightforward approach and
delivers at once the point mutations, gene fusions and gene
expression changes across the entire transcriptome. And as a
corollary, the data analysis strategies provided here would be
beneficial for any cancer type as long as a body of knowledge is
available for selecting and prioritizing candidate events.
Materials and Methods
Patient samples and cell lines
Diagnostic total RNAs from 31 T-ALL patients (20 adults and
11 children) were collected at various institutions. All patients have
given their informed consent and all samples were obtained
according to the guidelines of the local ethical committees. This
study was approved by the ethical committee of the University
Hospital Leuven. Diagnosis of T-ALL was based on morphology,
cytochemistry and immunophenotyping according to the World
Health Organization and European Group for the Immunological
Characterization of Leukemia criteria [77]. The clinical and
hematologic features of the 31 patients at the diagnosis are
summarized in Table S11 Total RNAs from 18 T-ALL cell lines
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(DSMZ, Braunschweig, Germany) were extracted using QIAGEN
RNeasy Mini Kit. A pool of total RNAs from 5 normal human
thymuses was purchased from Capital Biosciences.
All the RNA samples showed a high quality RNA Integrative
Number (RIN./ = 7) score on the Bioanalyzer (Agilent Technol-
ogies).
Fifty additional RNA samples were used for TPM3-JAK2 and
SSBP2-FER analysis.
Genomic DNA from of 71 adult T-ALL patients were used for
H3F3A K28 screening.
RNA-seq
Next generation sequencing libraries were constructed from
500 ng of total RNA using the Truseq RNA sample prep kit
(Illumina). RNA-seq libraries were subjected to 26100 bp paired-
end sequencing on a HiSeq2000 instrument (Illumina). Sequence
reads were processed to identify gene fusion transcripts, single
nucleotide variants (SNVs) and gene expression levels. For the
read mapping, variant calling and transcriptome assembly, we
used the infrastructure of the VSC - Flemish Supercomputer
Center, funded by the Hercules foundation and the Flemish
Government - department EWI.
Fusion transcript discovery
Fusion transcript discovery was performed using defuse v.0.5.0
[49] with default parameters. The resulting list was filtered as
described in [78]. Briefly, fusion transcripts with less than 8
spanning reads and less than 5 split reads were filtered out. In
addition, we removed fusion events observed in adjacent genes
and fusion events involving ribosomal genes (ribosomal genes were
downloaded from Biomart on 24-05-2011 using GO:0005840) and
the genes located on chrM. Fusion events were annotated using
Pegasus (http://sourceforge.net/projects/pegasus-fus/).
Gene expression analysis
For Gene Expression Profiling analysis, reads were mapped to
the human reference genome (assembly GRCh37.68) using
TopHat v.2.0.5 [26] with the following parameters: transcrip-
tome-only. Read counts per gene were obtained with the HTSeq
package (htseq-count) (http://www-huber.embl.de/users/anders/
HTSeq). The aggregated read counts were normalized with
EDASeq v1.4.0 [79] and generalized linear model was fitted with
edgeR v3.0.4 [73] to remove batch effect originating from the
sample collection center. The pathways, and upstream regulators
were generated through the use of IPA (Ingenuity Systems, www.
ingenuity.com). Expression neighbors were detected with Pavlidis
Template Matching (PTM) analysis [80]. Transcript based gene
expression values were obtained using cufflinks suite [81,82].
Transcript assembly was performed with cufflinks v2.1.1 with –g
option using assembly GRCh37.68.
Gene set enrichment analysis (GSEA) was performed for TAL1,
TLX and LYL1 clusters [83]. We have obtained whole genome
rankings for TAL1, TLX (TLX1 and TLX3), and LYL1 simply by
calculating the log fold changes between samples expressing the
respective gene versus the remaining samples. The gene signatures
from Soulier et al were obtained from Table S2 [41].
Alternative transcript event discovery
Tumor patient samples and Thymus RNA-Seq samples were
mapped to the Ensembl GRCh37.68 reference genome by
Tophat2 [26]. Mapped reads were realigned, and transcript
abundance were estimated using cufflinks v2.1.1 [81,82]. Tran-
script assembly was reconstructed using the cuffmerge program of
the cufflinks package from the realigned transfrags for each of
patient RNA-seq samples, merged with the Thymus sample
(control), followed by differential expression analysis performed
using cuffdiff program. The significant events were extracted from
the list of differentially expressed genes, isoforms, primary
transcripts and coding sequence and assessed manually with
IGV [84]. The mRNA sequences for novel SUZ12 and LCK
transcripts were extracted using gffread command of cufflinks, and
these sequences were translated using the translate tool of the
ExPASy Bioinformatics Resource Portal [85]. The longest ORF
sequence was used to verify the domain architecture of the
resulting proteins using SMART [86,87].
Prediction of single nucleotide variation
The sequence reads were mapped to the human reference
genome (assembly GRCh37.68) using TopHat2 setting the option
‘‘read-realign-edit-dist’’ to zero [26]. Duplicate removal process
was performed on the aligned reads using Picard v1.74 (http://
picard.sourceforge.net). Then SAMTools package v0.1.19+
(pulled from the git repository on 29-07-2013) [27] was used for
single nucleotide variant (SNV) and small insertion and deletion
(INDEL) detection with minimum mapping quality threshold of 1
and minimum base quality threshold of 13 (-q 1 -Q 13) [27]. The
variant calling was done on the coding regions of the genome only
(extracted from the transcript definitions in the assembly
GRCh37.68). The variant predictions that were supported
exclusively by variants located in the beginning or the end of the
read were filtered out. Then the SNVs were further filtered with
depth of coverage threshold of 20 and minimum variant allele
frequency threshold of 0.20. INDELs predictions were filtered
with the SAMTools recommended parameters (varFilter -10 -20 -
30 -40 -a4 -G90 -S30) and additionally INDELs located in
homopolymer stretches longer than 5 bps were filtered. The high
quality list of variants was filtered for common population variants
using the calls from 1000 genomes, dbSNP, HapMap, and
Complete Genomics. Note that, the list of common population
variants was cleaned from oncogenic variants using COSMIC
listed variants (v66) [36]. Moreover, the variants located in the
repeat regions (simple repeat and RepeatMasker) were filtered
out. Finally, the variants that are observed in the exomes of
remission (i.e. healthy) samples (including the previously published
39 exome remissions [17] and the 6 additional exome remission
sequenced) and the variants that are observed in Thymus were
also filtered out. The final filtered list of variants was annotated
with the Variant Effect Predictor version 2.7 [25] and the
protein-altering mutations were selected. The following terms
were used for selecting protein-altering SNVs: splice-donor-
variant, splice-acceptor-variant, stop-gained, initiator-codon-vari-
ant, missense-variant, splice-region-variant. The same terms
were used for filtering the INDELs with the addition of the
following terms: inframe-insertion, inframe-deletion, frameshift-
variant.
The list of candidate genes was created by intersecting the genes
with recurrent mutations (SNVs and INDELs) in RNA-seq patient
cohort with the somatic mutations in Exome-seq patient cohort
[17]. The list of genes that have recurrent mutations in the
RNA-seq patient cohort was filtered for mutations observed in
chrM.
The list of T-ALL driver genes were curated using the Census
database [46] and T-ALL literature and includes the following
genes: TLX1, TLX3, PHF6, MYC, BCL11B, HOXA1, SET, MLL,
MLLT1, PICALM, MLLT10, WT1, MYB, LEF1, LMO2, LMO1,
TAL1, NUP98, NOTCH1, FBXW7, CCND2, PTEN, PTPN2, NF1,
FLT3, JAK1, NRAS, LCK, NUP214, ABL1, EZH2, SETD2, SUZ12,
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JAK3, MEF2C, NKX2-1, NKX2-2, CDKN2A, CDKN2B, RUNX1,
KRAS, EED, ETV6, RPL10, DNM2, IL7R, CNOT3.
Exome-seq analysis
Somatic mutations from the exome pairs were obtained as
described previously [17]. Briefly, the alignment was performed
with BWA [22] and post-alignment modifications (duplicate
removal, realignment around INDELs and calibration of the
quality scores) were done with the Genome Analysis Toolkit
(GATK) [23]. Variant calling was performed with GATK using
Variant Quality Score Recalibration (VQSR) method. Putative
somatic variants were identified by subtracting the mutations
observed in the primary samples from the mutations observed in
the corresponding remission samples. SomaticSniper score above
70 was used to identify the final list of somatic events [24].
Variant allele frequency (VAF) plots were drawn for the
positions that are novel SNVs in either of the RNA-seq or
Exome-seq data and covered by at least 20 reads in both datasets.
RT-PCR and Sanger sequencing
Novel candidate fusion transcripts were validated by Reverse-
Transcription Polymerase-Chain-Reaction (RT-PCR) and Sanger
sequencing. In all cases Thymus was used as negative control.
cDNA synthesis and PCR amplification were performed using
standard protocols that come with Superscript III Reverse
Transcriptase (Invitrogen) and GoTaq (Promega). PCR primers
were designed to amplify 200–400 bp fragments containing the
fusion boundary detected by RNA-seq. The PCR products were
analyzed using a QIAxcel automated multicapillary electrophore-
sis system (QIAGEN). The results were processed and visualized
using the BioCalculator Software. PCR products were analyzed by
Sanger Sequencing. In cases where multiple PCR products were
detected, we performed conventional agarose gel electrophoresis
and extraction of specific bands using the gel DNA Recovery Kit
(Zymo). Analysis of Sanger chromatograms was performed using
CLC Main Workbench 6 (CLC Bio, Aarhus, Denmark). Fusion
detection was performed using NCBI Blast alignment. Analysis of
the breakpoint was done on the longest isoform reported on the
Ensembl genome browser. The tested fusions predictions and the
primers used for validations are reported in Table S12.
Validation of SUZ12 exon skipping was performed by RT-PCR,
gel extraction and sequencing of the two PCR products
(Figure 4.I). The following primers were used for RT-PCR and
Sanger sequencing: SUZ12_EX1F (CTGACCACGAGCTT
TTCCTC) and SUZ12_EX9R (CCATTTCCTGCATGGC-
TACT).
Cloning
The plasmid TPM3-JAK2 pMSCV-GFP was obtained as
follows: a DNA fragment containing TPM3 coding region till
exon 7 was PCR amplified from thymus cDNA using Phusion
High Fidelity DNA Polymerase (Finzyme) and primers containing
BglII and XhoI restriction sites. Primers containing XhoI and
EcoRI restriction sites were used to amplify JAK2 coding exons
17–25. PCR products were cloned into the BglII and EcoRI sites
of the pMSCV-GFP vector after subcloning into the pJET1.2
CloneJET vector (Fermentas). As a final control, plasmid DNA
was sequenced by Sanger sequencing.
SSBP2-FER fusion was synthesized by Genscript (Piscataway,
NJ, USA) and cloned into pMSCV-GFP by using the unique
restriction sites XhoI and EcoRI. The plasmid contained the full
length SSBP2-FER fusion including the first 16 coding exons of
SSBP2 and the coding exons 14–20 of FER.
Cell culture
Viral supernatants were produced in HEK293T cells using an
EcoPack packaging plasmid and TurboFect transfection reagent
(Fermentas). Viruses were harvested 48 hours after transfection
followed by transduction of the Ba/F3 murine pro-B cells (DSMZ,
Braunschweig, Germany) as described previously [88].
Transformation experiments
Ba/F3 cells were washed twice in PBS to remove all traces of
cytokines and were seeded in triplicate in 24-well dishes at 100 000
cells/mL. GFP expression and cell number were measure on a
Guava flow cytometer (Millipore). All experiments were terminat-
ed at day 8 after cytokine removal and cell lines showing no sign of
cell proliferation at that timepoint were declared to be non-
transforming.
Western blotting
Total cell lysates were analyzed by standard electrophoresis and
western blotting procedures using the following antibodies: anti-
phospho-JAK1 (Tyr1022/1023), anti-phospho-STAT1, anti–phos-
pho-STAT5 (Tyr694), anti–phospho-STAT3 (Tyr705), anti-phos-
phoERK1-2, anti-phospho-SRC families (Tyr416) (from Cell
Signaling Technology).
Inhibitor experiments
TPM3-JAK2 and SSBP2-FER IL3-independent Ba/F3 cells were
seeded in triplicate in 96-well plates at a density of 0.036106 cells
in the presence of JAK inhibitor Ruxolitinib (INCB018424, Azon
Medchem). Cell proliferation and viability were assessed on a
Guava flow cytometer after 24 hours to determine the IC50, the
concentration of inhibitor that gave a 50% inhibition.
Accession numbers
Genome data has been deposited at the European Genome-
phenome Archive (EGA, http://www.ebi.ac.uk/ega/) which is
hosted at the EBI, under accession number EGAS00001000536.
Supporting Information
Figure S1 Suboptimal mapping strategies result in incorrect
read alignment. Alignment of the Exome-seq and RNA-seq reads
on GLUD2 and GLUD1 genes for the RPMI8402 cell line. Two
alignment strategies are visualized in these figures for RNA-seq:
genome-only mapping and combined mapping strategy. Panel (A)
shows the alignment for GLUD2 gene. With exome-seq a very high
coverage was achieved (the coverage track scale is 0–1000).
Aligning the RNA-seq reads with ‘genome-only’ option yields high
coverage as well however with a lot of mismatches in the
alignment (colored lines indicate the presence of a nucleotide
different than the reference base). However, when combined
mapping strategy is applied the coverage drops drastically. Panel
(B) shows the alignment of GLUD1 gene. When mapping with
genome only option, the coverage is not high (the coverage track
scale is 0–900) since the reads are forced to map to the pseudogene
(GLUD2) with a lot of mismatched. When the combined mapping
strategy implemented, the reads align to GLUD1 gene correctly
with less mismatches.
(PDF)
Figure S2 Variant allele frequency plots for assessing transcrip-
tome-only mapping strategy. The variant allele frequencies of the
SNVs that have at least 206reads in exome-seq and RNA-seq are
plotted. The RNA-seq SNVs were obtained with the transcrip-
tome-only alignment option. Red and green dots represent the
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SNVs that are detected only in RNA-seq and only in exome-seq,
respectively, while black dots represent the SNVs that are called in
both. Venn diagrams are produced from the points represented in
the graphs. The plots are generated for (A) RPMI8402 cell line
and (B) TLE79 patient sample.
(PDF)
Figure S3 Variant Allele Frequency (VAF) plots for 16 cell lines
and 20 patient samples. RNA-seq calls are made with combined
mapping strategy. The venn diagrams and VAF plots are drawn
for variants that have sequence coverage of at least 206.
(PDF)
Figure S4 Scatter plot of average coverage versus recall ratio per
sample. Recall ratio per sample is calculated as the percentage of
Exome-seq SNVs that are called in the RNA-seq as well. Recall
ratio 0.3 is assumed as the indicator of a ‘good sample’ in terms of
variant detection.
(PDF)
Figure S5 Visualization of the alignments with Exome-seq and
RNA-seq for the 5 INDELs that are validated in the DNA of the
samples but absent in the RNA-seq alignments. The Exome-seq
and RNA-seq alignment files are visualized using IGV for (A)
KDM6A in TLE87, (B) PTEN in TLE92, (C) WT1 in TLE76, (D)
USP9X in SUPT1, and (E) UNC5D in MOLT4. The exome-seq
alignment files (below) have the reads containing the INDEL,
whereas RNA-seq alignment files (above) either contain reads with
reference only (A, B, and E) or a small portion of reads with
INDEL (C and D).
(PDF)
Figure S6 INDELs in TLE92 and TLE87 are detected after
mapping with a different aligner. The screenshots from UCSC
genome browser shows (A) the 4 bp deletion in PTEN (note that
only a part of the alignment was shown) and (B) 1 bp deletion in
KDM6A. In both cases BWA transcriptome-only mapping
was coupled to BLAT genome mapping. In (C) and (D), TopHat2
transcriptome-only mapping coupled with BLAT genome
mapping was displayed for PTEN and KMD6A INDELs,
respectively.
(PDF)
Figure S7 Batch effect removal for gene expression profiling.
Multidimensional scaling (MDS) plots before and after batch effect
removal. A batch effect was observed whereby samples originating
from the same collection center clustered together based on the
edgeR normalized gene-by-gene counts (A). A similar clustering
was observed when the FPKM values per transcript was used (B).
After fitting a Generalized Linear Model (on the edgeR
normalized gene-by-gene counts) accounting for sample collection
center, the aberrant clustering of the samples is corrected (C).
(PDF)
Figure S8 Overview of exon skipping event in LCK. (A)
Predicted novel transcript of LCK aligned with known LCK
isoforms. Dotted red box indicates the exon-skipping event in the
8th exon (B) Sashimi plot detailing the junction supporting the
exon skipping event in patient samples R5, R5 and TLE93 with
respect to Thymus. (C) Schematic representation of the predicted
alternative splicing event of LCK. The exon skipping ratio (C/
A+B+C) of exon 8 of LCK in R5, R4, TLE93 are 0.40, 0.47 and
0.20, respectively. (D) Schematic overview of LCK protein
illustrating the spliced out portion without affecting the functional
domains.
(PDF)
Figure S9 Schematic overview of the SUZ12 exon-skipping
event. (A) Schematic representation of the predicted alternative
splicing event of SUZ12. The exon skipping ratio (C/A+B+C) of
exon 7 of SUZ12 in R5 is 0.35. (B) Schematic overview of SUZ12
protein illustrating the spliced out portion without affecting the
functional domains.
(PDF)
Figure S10 Out-of-frame fusions can have various consequenc-
es. The over or under expression caused by out-of-frame
gene fusions are illustrated in the normalized expression heatmap.
CLINT1-MEF2C, HNRP-ZNF219, ZEB1-BMI1 and AHI1-MYB
fusion are associated with overexpression of MEF2C, ZNF219,
BMI1 and MYB; whereas as TP53-TBC1D3F, PTEN-RNLS,
IKZF1-ABCA13 and CDKN2A-miR31HG fusions are responsible
for the under-expression of TP53, PTEN, IKZF1 and CDKN2A.
(PDF)
Table S1 (A) Sequencing and mapping statistics, (B) Variant
statistics, (C) Fusion statistics.
(XLSX)
Table S2 Samples analyzed in this study.
(XLSX)
Table S3 Comparison of the number of novel SNV and
INDELs between RNAseq and Exome-seq.
(XLSX)
Table S4 Validated INDELs from the Exome-seq.
(XLSX)
Table S5 Mutations detected in 213 genes.
(XLSX)
Table S6 IPA on 213 candidate genes.
(XLSX)
Table S7 ENDEAVOUR results on 213 genes.
(XLSX)
Table S8 ATEs identified in known T-ALL drivers.
(XLSX)
Table S9 Fusions detected in 49 samples and the Thymus.
(XLSX)
Table S10 Annotation of fusions with Pegasus.
(XLSX)
Table S11 Patient characteristics.
(XLSX)
Table S12 Novel Fusion Transcript validated by RT-PCR and
Sanger sequencing.
(XLSX)
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